ALIVUS LIFE SCIENCES LIMITED

About

Alivus Life Sciences Limited develops and manufactures active pharmaceutical ingredients in India, the United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China, and Australia. It offers various APIs, such as amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, solifenacin, atovaquone, etoricoxib, dapagliflozin, and sitagliptin for therapeutic areas, including cardiovascular, central nervous system, diabetes, oncology, urology, and pain management, as well as anti-fungal, anti-histaminic, anti-acne, anti-emetics immunomodulators, anti-ulceratives, immunosuppressant, respiratory agent, ophthalmologic agent, anti-spasmodic, and urology. The company also provides contract development and manufacturing comprising process development, analytical development and support, and API and intermediate manufacturing; and research and development, intellectual property, quality and compliance, customer experience, regulatory support. In addition, it exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited operates as a subsidiary of Nirma Limited.

Key Metrics

as of Sep 2026

Market Cap16,774 Cr

P/E47.70

Div Yield0.37 %

Book Value—

52w High₹1,495.00

52w Low₹819.00

Face Value₹2.00

Quarterly Results

Rs. Crores · hover row for definition

Metric	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023
Sales	640.00	689.00	673.00	588.00	602.00	650.00	642.00	507.00	589.00	537.00	573.00	595.00	578.00
Expenses	429.00	475.00	442.00	409.00	430.00	451.00	452.00	373.00	429.00	395.00	400.00	428.00	385.00
Operating Profit	212.00	215.00	231.00	179.00	172.00	198.00	190.00	134.00	159.00	141.00	173.00	167.00	193.00
OPM %	33.00	31.00	34.00	30.00	29.00	31.00	30.00	27.00	27.00	26.00	30.00	28.00	33.00
Other Income	22.00	23.00	-12.00	15.00	9.00	10.00	10.00	9.00	5.00	3.00	2.00	5.00	2.00
Depreciation	21.00	20.00	20.00	18.00	17.00	16.00	15.00	15.00	14.00	15.00	13.00	13.00	13.00
Interest	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Profit before tax	212.00	216.00	198.00	174.00	163.00	191.00	185.00	127.00	150.00	130.00	161.00	159.00	182.00
Tax %	25.00	25.00	24.00	25.00	25.00	26.00	26.00	25.00	26.00	24.00	26.00	25.00	26.00
Net Profit	160.00	163.00	150.00	130.00	122.00	142.00	137.00	95.00	111.00	98.00	119.00	119.00	135.00
EPS in Rs	13.04	13.25	12.25	10.60	9.91	11.58	11.18	7.78	9.10	7.99	9.69	9.69	11.05

Profit & Loss

Annual · Rs. Crores

Metric	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018
Sales	2,552.00	2,387.00	2,283.00	2,161.00	2,123.00	1,885.00	1,537.00	886.00	0.00
Expenses	1,754.00	1,702.00	1,608.00	1,518.00	1,506.00	1,294.00	1,064.00	638.00	0.00
Operating Profit	798.00	684.00	675.00	643.00	617.00	592.00	473.00	248.00	0.00
OPM %	31.00	29.00	30.00	30.00	29.00	31.00	31.00	28.00	-4.00
Other Income	34.00	33.00	11.00	28.00	14.00	0.00	11.00	0.00	0.00
Interest	5.00	2.00	2.00	1.00	28.00	88.00	34.00	1.00	0.00
Depreciation	75.00	61.00	53.00	42.00	38.00	33.00	29.00	19.00	0.00
Profit before tax	751.00	654.00	631.00	629.00	565.00	471.00	421.00	228.00	0.00
Tax %	25.00	26.00	25.00	26.00	26.00	25.00	26.00	14.00	4,200.00
Net Profit	564.00	486.00	471.00	467.00	419.00	352.00	313.00	196.00	0.00
EPS in Rs	45.99	39.63	38.43	38.11	34.17	358.74	1,597.37	997.86	-430.00
Dividend Payout %	11.00	13.00	59.00	110.00	61.00	0.00	0.00	0.00	0.00

Balance Sheet

Annual · Rs. Crores — latest first

Metric	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018
Equity Capital	25.00	25.00	25.00	25.00	25.00	2.00	2.00	2.00	0.01
Reserves	3,308.00	2,793.00	2,308.00	2,114.00	2,030.00	751.00	400.00	86.00	-1.00
Borrowings	57.00	57.00	17.00	19.00	3.00	0.00	0.00	0.00	0.00
Other Liabilities	594.00	537.00	501.00	545.00	414.00	1,244.00	1,324.00	1,387.00	1.00
Total Liabilities	3,983.00	3,411.00	2,850.00	2,702.00	2,471.00	1,997.00	1,726.00	1,475.00	0.00
Fixed Assets	1,038.00	955.00	805.00	781.00	595.00	573.00	546.00	456.00	0.00
CWIP	284.00	102.00	106.00	62.00	92.00	14.00	11.00	80.00	0.00
Investments	780.00	478.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	1,881.00	1,877.00	1,939.00	1,860.00	1,784.00	1,410.00	1,169.00	939.00	0.00
Total Assets	3,983.00	3,411.00	2,850.00	2,702.00	2,471.00	1,997.00	1,726.00	1,475.00	0.00

Cash Flows

Annual · Rs. Crores — latest first

Metric	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018
Cash from Operating Activity	565.00	392.00	414.00	306.00	598.00	388.00	195.00	10.00	0.00
Cash from Investing Activity	-570.00	-616.00	-116.00	-147.00	-122.00	-69.00	-51.00	-9.00	0.00
Cash from Financing Activity	-64.00	-6.00	-279.00	-388.00	-79.00	-214.00	-137.00	1.00	0.00
Net Cash Flow	-69.00	-230.00	18.00	-228.00	397.00	106.00	8.00	2.00	0.00
Free Cash Flow	259.00	226.00	285.00	143.00	466.00	322.00	144.00	1.00	0.00
CFO/OP %	93.00	81.00	85.00	71.00	119.00	84.00	61.00	14.00	4,800.00

Ratios

Annual · Days / % — latest first

Metric	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018
Debtor Days	153.00	148.00	122.00	136.00	116.00	120.00	152.00	185.00	44.00
Inventory Days	246.00	237.00	251.00	224.00	185.00	214.00	227.00	441.00	162.00
Days Payable	132.00	137.00	139.00	158.00	110.00	92.00	111.00	201.00	41.00
Cash Conversion Cycle	267.00	248.00	235.00	202.00	190.00	241.00	268.00	424.00	165.00
Working Capital Days	194.00	201.00	188.00	176.00	149.00	12.00	-37.00	-186.00	-2,059.00
ROCE %	24.00	25.00	28.00	30.00	42.00	97.00	186.00	529.00	—

Shareholding Pattern

% holding — latest first

Holder	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Promoters	74.87	74.87	74.91	74.91	74.94	74.99	75.00	75.00	82.85	82.85	82.85	82.85
FIIs	5.54	5.30	5.08	6.84	6.42	6.57	6.74	7.85	4.81	5.01	4.57	4.39
DIIs	7.18	7.27	7.13	5.47	5.62	5.19	4.86	4.16	1.57	1.41	0.74	0.64
Public	12.42	12.55	12.89	12.79	13.03	13.25	13.40	12.99	10.76	10.73	11.84	12.13
No. of Shareholders	125,559	127,969	132,748	135,643	138,500	141,977	146,840	143,960	149,396	156,183	185,531	198,764

Corporate Actions

6 records

Action	Ex Date	Record Date	Ratio	Amount (₹)	Notes
Dividend	01 Sep 2025	01 Sep 2025	—	5.00
Dividend	17 Oct 2023	17 Oct 2023	—	22.50
Other	22 Sep 2023	—	—	—	Annual General Meeting
Dividend	24 Mar 2023	24 Mar 2023	—	21.00
Dividend	15 Sep 2022	—	—	10.50
Dividend	22 Nov 2021	23 Nov 2021	—	10.50

Announcements

5 filings

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 5 Sep
05 Sep 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
25 Aug 2026 25 Aug - Alivus Life Sciences will hold four one-on-one investor meetings from August 28 to September 2, 2026.
Announcement under Regulation 30 (LODR)-Acquisition
18 Aug 2026 18 Aug - Board approved 76% stake acquisition in IQGEN-X Pharma for about Rs 9.12 crore.
Announcement under Regulation 30 (LODR)-Press Release / Media Release
18 Aug 2026 18 Aug - Alivus Life Sciences to acquire 76% stake in IQGenX for INR 91.2 million, closing expected by year-end.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
13 Aug 2026 13 Aug - Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting